Coronavirus Update: With New Data, Don’t Count J&J Out Yet
Executive Summary
J&J announced strong data for its single-shot vaccine, with even stronger booster shot data to boot. Also Gilead posted strong results for outpatient use of Veklury, but it faces stiff competition, while Clover announced new data and Pfizer/BioNTech sold another 500 million vaccine doses for donation.
You may also be interested in...
J&J's Longtime R&D Head Stoffels To Retire, Raising The Leadership Transition Stakes
Chief scientific officer Paul Stoffels will retire at the end of the year at the same time CEO Alex Gorsky will hand over the top leadership role to Joaquin Duato; no successor has been named.
Moderna Reports ‘Robust’ Response From COVID-19 Booster Shots
Executives said the company was “capacity constrained” for 2021 and not taking further mRNA-1273 vaccine orders for delivery this year.
Coronavirus Update: Regeneron's REGEN-COV Authorized For Prevention
Regeneron's antibody cocktail gets emergency authorization for post-exposure prophylaxis from the US FDA. Daewoong's camostat shows efficacy in older patients in South Korean trial.